Company intelligence / Profile preview

MC2 Therapeutics

Hørsholm, Denmark

Ownership: Private
Development stage: Commercial

Overview

MC2 Therapeutics has a marketed product Wynzora® Cream for plaque psoriasis and multiple Phase 2 candidates in development. Their lead candidate MC2-32 received positive FDA pre-IND feedback for Hidradenitis Suppurativa treatment, with IND filing anticipated in mid-2025. They also have MC2-25 in Phase 2a for Vulvar Lichen Sclerosus with topline results expected in Q4 2024.

Therapeutic areas: ImmunologyDermatology
Modalities: Small moleculestopical formulations
Industry: Biotech

Drug pipeline

6 assets

MC2-25 cream

5 more assets in the full pipeline.

Request access →

Partnerships

Paladin Pharma Inc. (subsidiary of Endo, Inc.)partnerships covering more than 40 countries across four continents

Beyond the preview

Go deeper on MC2 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC2 Therapeutics.

Explore the full profile